Press release content from News Direct Corporation. The AP news staff was not involved in its creation.

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

PRESS RELEASE: Paid content from News Direct Corporation
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
January 10, 2023 GMT
None
None

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.

Proactive Canada Financial News

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-releases-details-of-phase-2b-chronic-cough-study-of-ifenprodil-669427862